NewAmsterdam Pharma Files 8-K

TL;DR

NAMS filed an 8-K on Aug 18, 2025, mostly procedural stuff.

AI Summary

On August 18, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates NewAmsterdam Pharma is making disclosures required by the SEC, which could relate to ongoing business operations or regulatory compliance.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing cover page and does not contain information about specific risks or material events.

Key Players & Entities

• NewAmsterdam Pharma Company N.V. (company) — Registrant
• August 18, 2025 (date) — Date of Report
• 001-41562 (company) — Commission File Number

FAQ

Filing Documents

• nams-20250818.htm (8-K) — 58KB
• nams-ex99_1.htm (EX-99.1) — 36KB
• 0000950170-25-109567.txt ( ) — 249KB
• nams-20250818.xsd (EX-101.SCH) — 54KB
• nams-20250818_htm.xml (XML) — 6KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 18, 2025, NewAmsterdam Pharma Company N.V. (the "Company") issued a press release announcing that the European Medicines Agency (the "EMA") has validated the Marketing Authorization Application (the "MAA") for obicetrapib 10 mg monotherapy and 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination for patients with primary hypercholesterolemia, both heterozygous familial and non-familial or mixed dyslipidemia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

01 Other Events

Item 8.01 Other Events. On August 18, 2025, the Company announced that the EMA has validated the MAA referred to above. The validation allows for substantive review by the EMA of the Company's BROADWAY, BROOKLYN and TANDEM Phase 3 clinical trials. The MAA was submitted by the Company's partner, A. Menarini International Licensing S.A., who is responsible for communications with regulatory authorities in Europe and for the commercialization and local development of obicetrapib in Europe and other collaborative activities pursuant to an exclusive license agreement with NewAmsterdam Pharma B.V., a subsidiary of the Company.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. Date: August 18, 2025 By: /s/ Michael Davidson Name: Michael Davidson, M.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR